Literatur

• Literatur

• 1 Berlan M, Montastruc JL, Lafontan M. Pharmacological prospects for alpha 2 adrenoceptor antagonist therapy. Trends Pharmacol Sci 1992; 13 (07) 277-282.
• 2 Costa J, Rocha ML, Ferreira J, Evangelista T, Coelho M, de Carvalho M. Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis. J Neurol 2008; 255 (04) 545-550.
• 3 Kahl KG, Trillenberg P, Kordon A, Lencer R, Klein C, Hagenah J. Pharmacological strategies for clozapine-induced hypersalivation: treatment with Botulinum toxin B in one patient and review of the literature. Nervenarzt 2005; 76 (02) 205-208.
• 4 Kahl KG, Hagenah J, Zapf S, Trillenberg P, Klein C, Lencer R. Botulinum toxin as an effective treatment of clozapine-induced hypersalivation. Psychopharmacology (Berl) 2004; 173 (1–2) 229-230.
• 5 Mier RJ, Bachrach SJ, Lakin RC, Barker T, Childs J, Moran M. Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study. Arch Pediatr Adolesc Med 2000; 154 (12) 1214-1218.
• 6 Santamato A, Ianieri G, Ranieri M, Megna M, Panza F, Fiore P, Megna G. Botulinum Toxin type A in the treatment of sialorrhea in Parkinson’s disease. J Am Geriatr Soc 2008; 56 (04) 765-767.
• 7 Schneider B, Weigmann H, Hiemke C, Weber B, Fritze J. Reduction of clozapine-induced hypersalivation by pirenzepine is safe. Pharmacopsychiatry 2004; 37 (02) 43-45.
• 8 Sockalingam S, Shammi C, Remington G. Clozapine-induced hypersalivation: a review of treatment strategies. Can J Psychiatry 2007; 52 (06) 377-384.
• 9 Stone CA, O’Leary N. Systematic Review of the Effectiveness of Botulinum Toxin or Radiotherapy for Sialorrhea in Patients with Amyotrophic Lateral Sclerosis. J Pain Symptom Manage 2009; 37 (02) 246-258.